We will contact you shortly.
A strategy to kill solid tumors in a tissue-agnostic manner
Tumors depend on tumor blood vessels to grow and metastasize. We are developing a new generation of anti-angiogenic drugs designed to both inhibit and kill tumors by killing tumor blood vessels.
Our target is highly specific; it is only found in tumor blood vessels.
At the same time, our target is very broad; it is present in the tumor blood vessels of most solid tumors.
Kills Tumor Blood Vessels
Our approach disrupts new tumor blood vessel growth that is mediated by multiple different angiogenic factors and results in the death of existing tumor blood vessels.
Suppress and Kill Solid Tumors
Our approach both suppresses tumor growth and kills existing tumors.
Less Susceptible to Mutagenesis
Since we are not targeting cancer cells, our approach is less susceptible to mutagenesis.
Dr. Sun is a co-founder of Atengen and has served as the company’s Chief Executive Officer since its founding in August of 2017. Prior to starting Atengen, Dr. Sun’s career focused on the development of automated and high throughput solutions for a broad spectrum of research areas, including small and large molecule pharmaceutical research.
Dr. Sarret has served as Atengen’s Chief Business Officer since September 2019. He has over 15 years of experience in structuring and successfully implementing complex life sciences transactions. Prior to joining Atengen, he served as Chief Business Officer for Corium International, a commercial-stage biopharmaceutical company.